Given that an mRNA-based strategy has been developed to target HNF4A in preclinical models for liver fibrosis (Yang et al, 2021), similar strategy can be used to control the development of gastrointestinal adenocarcinoma with HNF4A-dependent overexpression of MYB. This evidence concerns the gene MYB and Hepatic fibrosis.